"Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids"@en . . . . "Rituximab"@en . . "The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis."@en . . . . . "Humans and other mammals"@en . "174722-31-7"@en . . . . " "@en . . . . . . "* 0.34 L/day [RA patients]"@en . "AntiCD20"@en . "# McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9704735 # Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572-81. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15201414 # Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005 Apr;78(4):275-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15795920 # Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M: The epitope recognized by rituximab. Blood. 2006 Sep 15;108(6):1975-8. Epub 2006 May 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16705086 # Burton C, Kaczmarski R, Jan-Mohamed R: Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003 Jun 26;348(26):2690-1; discussion 2690-1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12826649 # http://www.google.com/patents/EP2231183A2?cl=en # http://planetorbitrap.com/data/uploads/528fce2e395be.pdf"@en . "For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis."@en . . "Ig gamma-1 chain C region"@en . "0.8 hours (mammalian reticulocytes, in vitro)"@en . "* 3.1 L"@en . . . . . . . . . . . . . . "approved"@en .